BA
Balaxi Pharmaceuticals Ltd (BALAXI)
₹33.57
Mkt cap
₹129 Cr
P/E ratio
38.40
P/B
0.73
Div yield
0.00%
ROE
0.59%
ROCE
3.47%
EPS (TTM)
₹0.87
Book value
₹46
52W range
15–41
Sector
Healthcare
Price history
Previous close
Balaxi Pharmaceuticals Ltd is an IPR-based pharmaceutical Company engaged in producing, stocking, selling, and supplying branded and generic medicines. [1]
NSE BALAXI
Health check
Mixed
ValuationFair
ProfitabilityWeak
GrowthHigh
TechnicalsNeutral
52-week range
−18.08% from high₹34
₹15+120.86% from low₹41
Current
₹33.57
Prev close
₹37.30
Day
−10.00%
Price performance
1D
−10.00%
1W
+43.22%
1M
+59.86%
3M
+50.54%
6M
+34.07%
1Y
−10.31%
YTD
+24.06%
Financials
Revenue, profit & margin
P/E ratio
38.4×
BALAXI is 13% above the sector median of 34.0×
BALAXI38.4×
Sector median34.0×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 54.72 | 60.79 | 59.83 | 65.62 | 77.38 | 73.29 | 76.27 | 70.74 | 56.18 | 72.54 | 70.71 | 80.68 | 81.37 | |
| YoY Sales growth | -36.65% | -29.79% | -25.84% | -0.52% | +41.41% | +20.56% | +27.48% | +7.80% | -27.40% | -1.02% | -7.29% | +14.05% | +44.84% | |
| Expenses | 43.96 | 47.14 | 46.36 | 55.53 | 66.79 | 69.30 | 63.72 | 66.58 | 55.02 | 69.45 | 70.59 | 76.02 | 76.24 | |
| Operating Profit | 10.76 | 13.65 | 13.47 | 10.09 | 10.59 | 3.99 | 12.55 | 4.16 | 1.16 | 3.09 | 0.12 | 4.66 | 5.13 | |
| OPM % | 19.66% | 22.45% | 22.51% | 15.38% | 13.69% | 5.44% | 16.45% | 5.88% | 2.06% | 4.26% | 0.17% | 5.78% | 6.30% | |
| Other Income | 5.93 | 1.51 | -0.70 | -1.85 | -4.11 | 3.94 | -1.69 | -1.78 | 1.59 | 0.10 | 2.92 | -0.99 | -0.83 | |
| Interest | 0.37 | 0.41 | 0.61 | 0.37 | 0.45 | 1.38 | 0.74 | 1.01 | 0.89 | 1.02 | 0.99 | 0.73 | 0.86 | |
| Depreciation | 0.66 | 0.48 | 0.67 | 0.49 | 0.46 | 0.48 | 0.46 | 0.46 | 0.48 | 0.56 | 0.65 | 0.85 | 1.42 | |
| Profit before tax | 15.66 | 14.27 | 11.49 | 7.38 | 5.57 | 6.07 | 9.66 | 0.91 | 1.38 | 1.61 | 1.40 | 2.09 | 2.02 | |
| Tax % | 7.92% | 4.77% | 4.87% | 12.06% | 17.41% | 11.70% | 10.56% | 67.03% | 84.06% | 80.75% | 56.43% | 38.28% | 43.07% | |
| Net Profit | 14.43 | 13.59 | 10.93 | 6.48 | 4.59 | 5.36 | 8.64 | 0.29 | 0.21 | 0.31 | 0.61 | 1.30 | 1.15 | |
| EPS in Rs | 2.82 | 2.65 | 2.01 | 1.17 | 0.83 | 0.97 | 1.57 | 0.05 | 0.04 | 0.06 | 0.11 | 0.24 | 0.21 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202665.99%Promoter
Promoters65.99%
FIIs0.00%
DIIs2.56%
Public31.45%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,880.00 | 36.66 | 4,51,075 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,442.00 | 88.89 | 3,03,749 | 0.26% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,670.00 | 81.82 | 1,77,632 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,424.00 | 97.75 | 1,30,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,189.90 | 26.20 | 1,18,693 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,380.00 | 41.17 | 1,15,267 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,391.80 | 36.21 | 1,12,442 | 0.93% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Balaxi Pharma | ₹23.44 | 38.40 | 129 | 0.00% | 1 | +447.62% | 81 | +44.84% | 3.47% |
| Median: 160 Co. | ₹465.83 | 33.99 | 2,012 | 0.08% | 13 | +33.53% | 179 | +20.92% | 14.94% |
Filings
Annual reports11
Concall transcripts32
Credit ratings5
Announcements5
Copy of Newspaper Publication 14 Nov - Published unaudited standalone and consolidated results for quarter and half year ended 30 September 2026.Press Release 12 Nov - Q2 FY27 revenue rose 45% to ₹81.37 crore; EBITDA up 338%, PAT up 450%; Jadcherla facility operational.Updates 12 Nov - Board approved Q2 FY26 results and noted WHO-GMP certification; Jadcherla plant now has 34 approved products.Change in Management 12 Nov - Q2 FY26 results approved; Jadcherla plant received WHO-GMP certification, producing 22 products with 34 approved.Outcome of Board Meeting 12 Nov - Board approved Q2 FY26 results; Jadcherla plant received WHO-GMP certification and scaled production, with 34 products approved.






